MDC1 promotes ovarian cancer metastasis by inducing epithelial-mesenchymal transition

Tumor Biology

Volumn 36, Issue 6, 2015, Pages 4261-4269

  Liu, Xiaolin ^a   Dong, Ruifen ^a   Jiang, Zhijun ^a   Wei, Yuyan ^a   Li, Yingwei ^a   Wei, Linxuan ^a   Sun, Hengzi ^a   Li, Yinuo ^a   Yang, Ning ^a   Yang, Qifeng ^a   Liu, Zhaojian ^b   Kong, Beihua ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

EMT; MDC1; Metastasis; Ovarian cancer

Indexed keywords

MEDIATOR OF DNA DAMAGE CHECKPOINT 1; NERVE CELL ADHESION MOLECULE; NUCLEAR PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; CADHERIN; MDC1 PROTEIN, HUMAN; SMALL INTERFERING RNA; TRANSACTIVATOR PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CANCER TISSUE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DAMAGE CHECKPOINT; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MAJOR CLINICAL STUDY; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; AGED; ANIMAL; BIOSYNTHESIS; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION;

ADULT; AGED; ANIMALS; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; RNA, SMALL INTERFERING; TRANS-ACTIVATORS; VIMENTIN;

EID: 84938961065     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3063-5     Document Type: Article

References (32)

1. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61:183–203.
2. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–15.
3. De Craene B, Berx G. Regulatory networks defining emt during cancer initiation and progression. Nat Rev Cancer. 2013;13:97–110.
4. Kim MK, Kim MA, Kim H, Kim YB, Song YS. Expression profiles of epithelial-mesenchymal transition-associated proteins in epithelial ovarian carcinoma. BioMed Res Int. 2014;2014:495754.
5. Huang RY, Chung VY, Thiery JP. Targeting pathways contributing to epithelial-mesenchymal transition (emt) in epithelial ovarian cancer. Curr Drug Targets. 2012;13:1649–53.
6. Vergara D, Merlot B, Lucot JP, Collinet P, Vinatier D, Fournier I, et al. Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett. 2010;291:59–66.
7. Stucki M, Jackson SP. Mdc1/nfbd1: A key regulator of the DNA damage response in higher eukaryotes. DNA Repair. 2004;3:953–7.
8. Coster G, Goldberg M. The cellular response to DNA damage: A focus on mdc1 and its interacting proteins. Nucleus. 2010;1:166–78.
9. Jungmichel S, Stucki M. Mdc1: The art of keeping things in focus. Chromosoma. 2010;119:337–49.
10. Lou Z, Minter-Dykhouse K, Franco S, Gostissa M, Rivera MA, Celeste A, et al. Mdc1 maintains genomic stability by participating in the amplification of atm-dependent DNA damage signals. Mol Cell. 2006;21:187–200.
11. Stewart GS, Wang B, Bignell CR, Taylor AM, Elledge SJ. Mdc1 is a mediator of the mammalian DNA damage checkpoint. Nature. 2003;421:961–6.
12. Stucki M, Clapperton JA, Mohammad D, Yaffe MB, Smerdon SJ, Jackson SP. Mdc1 directly binds phosphorylated histone h2ax to regulate cellular responses to DNA double-strand breaks. Cell. 2005;123:1213–26.
13. d’Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature. 2003;426:194–8.
14. Goldberg M, Stucki M, Falck J, D’Amours D, Rahman D, Pappin D, et al. Mdc1 is required for the intra-s-phase DNA damage checkpoint. Nature. 2003;421:952–6.
15. Lou Z, Minter-Dykhouse K, Wu X, Chen J. Mdc1 is coupled to activated chk2 in mammalian DNA damage response pathways. Nature. 2003;421:957–61.
16. Nakanishi M, Ozaki T, Yamamoto H, Hanamoto T, Kikuchi H, Furuya K, et al. Nfbd1/mdc1 associates with p53 and regulates its function at the crossroad between cell survival and death in response to DNA damage. J Biol Chem. 2007;282:22993–3004.
17. Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer. 2012;12:587–98.
18. Watanabe S, Watanabe K, Akimov V, Bartkova J, Blagoev B, Lukas J, et al. Jmjd1c demethylates mdc1 to regulate the rnf8 and brca1-mediated chromatin response to DNA breaks. Nat Struct Mol Biol. 2013;20:1425–33.
19. Meng XW, Koh BD, Zhang JS, Flatten KS, Schneider PA, Billadeau DD, et al. Poly (adp-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression. J Biol Chem. 2014;289:20543–58.
20. Yang Z, Bu Y, Wang C, Liu G, Song F. Growth inhibition, morphology change, and cell cycle alterations in nfbd1-depleted human esophageal cancer cells. Mol Cell Biochem. 2010;342:1–6.
21. Yuan C, Bu Y, Wang C, Yi F, Yang Z, Huang X, et al. Nfbd1/mdc1 is a protein of oncogenic potential in human cervical cancer. Mol Cell Biochem. 2012;359:333–46.
22. Ye Q, Chen L, Yin X, Liu YJ, Ji Q, Zhao E: Development of serous ovarian cancer is associated with the expression of homologous recombination pathway proteins. Pathology oncology research. POR. 2014.
23. Campeau E, Ruhl VE, Rodier F, Smith CL, Rahmberg BL, Fuss JO, et al. A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS One. 2009;4:e6529.
24. Welcsh PL, King MC. Brca1 and brca2 and the genetics of breast and ovarian cancer. Hum Mol Genet. 2001;10:705–13.
25. Foulkes WD, Shuen AY. In brief: Brca1 and brca2. J Pathol. 2013;230:347–9.
26. Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer. 2012;12:801–17.
27. Goodwin JF, Knudsen KE: Beyond DNA repair: DNA-pk function in cancer. Cancer discovery. 2014.
28. Powell E, Piwnica-Worms D, Piwnica-Worms H. Contribution of p53 to metastasis. Cancer Discov. 2014;4:405–14.
29. Masutani M, Fujimori H. Poly (adp-ribosyl) ation in carcinogenesis. Mol Aspects Med. 2013;34:1202–16.
30. Broustas CG, Lieberman HB. DNA damage response genes and the development of cancer metastasis. Radiat Res. 2014;181:111–30.
31. Bartkova J, Horejsi Z, Sehested M, Nesland JM, Rajpert-De Meyts E, Skakkebaek NE, et al. DNA damage response mediators mdc1 and 53 bp1: Constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours. Oncogene. 2007;26:7414–22.
32. Wang B, Zhang L, Qiu F, Fang W, Deng J, Zhou Y, et al. A newfound association between mdc1 functional polymorphism and lung cancer risk in chinese. PLoS One. 2014;9:e106794.